


TL033

Chemical Properties

CAS No. : 2356230-22-1
 Formula: C76H103N13O23S2
 Molecular Weight: 1630.83
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	TL033 forms a component of an antibody-drug conjugate (ADC) as a drug-linker conjugate. It comprises a linker and a bioactive small molecule toxin. TL033 can be conjugated with the Sacituzumab antibody (anti-Trop-2) to synthesize BT001021, which exhibits anticancer activity against various cancers, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.
Targets(IC50)	Drug-Linker Conjugates for ADC
In vitro	BT001021 exhibits cytotoxicity against HCC1806 cells (a breast cancer cell line) with an EC50 of 13.15 nM over 3 days.
In vivo	BT001021, administered via intravenous injection at 3 mg/kg twice weekly for six doses, effectively suppresses tumor growth in the NCI-N87 gastric cancer xenograft mouse model, leading to tumor regression by the end of treatment. Additionally, a single 10 mg/kg dose of BT001021 (intravenous injection) demonstrates significant tumor tissue targeting and favorable pharmacokinetic properties.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.6132 mL	3.0659 mL	6.1318 mL
5 mM	0.1226 mL	0.6132 mL	1.2264 mL
10 mM	0.0613 mL	0.3066 mL	0.6132 mL
50 mM	0.0123 mL	0.0613 mL	0.1226 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481